TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00336375
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment doses given either accompanied or not-accompanied with intake of fatty food.
Study: NCT02961816
Drug: Caphosol
Normalized name: Caphosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caphosol oral rinses 30 mL four times a day used from Day -8.
Study: NCT02961816
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg by vein or mouth three times a day from Day -1.
Study: NCT06584773
Drug: standard maintenance immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone
Study: NCT01792206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
Study: NCT05080361
Drug: BRAF inhibitor
Normalized name: B-Raf serine-threonine kinase (BRAF) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.
Study: NCT00445744
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00445744
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01245816
Drug: Eflornithine plus Sulindac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
Study: NCT01245816
Drug: Eflornithine plus Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
Study: NCT01245816
Drug: Sulindac plus Placebo
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
Study: NCT01230216
Drug: control systolic blood pressure less than 120 mmHg
Approvals — FDA: no, EMA: no, PMDA: no
Description: use losartan to control blood pressure
Study: NCT01230216
Drug: control systolic blood pressure less than 140 mmHg
Approvals — FDA: no, EMA: no, PMDA: no
Description: use losartan to control blood pressure
Study: NCT00427999
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00672399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
Study: NCT01510535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: First 2 weeks Placebo(2ml) once weekly in experimental group
Study: NCT01510535
Drug: Hyruan Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group
Study: NCT01510535
Drug: LBSA0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: at third week LBSA0103(60mg) once in experimental group
Study: NCT01562821
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial placebo bolus dose followed by placebo every second hour until completion of surgery
Study: NCT02736591
Drug: Growth Hormone-Releasing Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
Study: NCT02736591
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.
Study: NCT02736591
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
Study: NCT01370564
Drug: Diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Study: NCT03000530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02014922
Drug: TheraTears® Lubricant Eye Drop
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02014922
Drug: TheraTears® preservative-free single-use containers
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00104468
Drug: Troxatyl™ (Cytotoxic Chemotherapeutic)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01982461
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg,once daily
Study: NCT01982461
Drug: Crestor®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg,once daily
Study: NCT01618916
Drug: LY3015014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02804815
Drug: Placebo 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 100mg
Study: NCT02804815
Drug: Placebo 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 300mg
Study: NCT00865241
Drug: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Study: NCT00655512
Drug: hydrocortisonacetat 1% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
Study: NCT00655512
Drug: betamethasonvalerat 0,1% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
Study: NCT00655512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
Study: NCT01507402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (inactive substance)
Study: NCT02963922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected subcutaneously (s.c., under the skin) once daily
Study: NCT03554200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care + Placebo: Matching Placebo (tablets) once daily
Study: NCT02784535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01839799
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
Study: NCT03735368
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral capsules
Study: NCT03735368
Drug: topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops
Study: NCT00580047
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4mg IV Annually
Study: NCT02020551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01836809
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
Study: NCT01478256
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical erythromycin ointment twice a day
Study: NCT04671251
Drug: AEVI-007
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
Study: NCT02275351
Drug: SM04554
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution, applied once a day
Study: NCT04150250
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy may include:~* Ciprofloxacin 500 mg, twice daily;~* Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~* Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)
Study: NCT01339156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A:~The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).
Study: NCT01825785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT03317457
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline
Study: NCT01285492
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
Study: NCT03362853
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive a single dose in a fasting state
Study: NCT01918852
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003541
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00475878
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule/day for 3 months
Study: NCT00096993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was provided as a single-use formulation for infusion.
Study: NCT02865811
Drug: Pegylated Liposomal Doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please see Arms for description.
Study: NCT03787680
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg by mouth daily for days 1-7 of a 28-day cycle.
Study: NCT00003541
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003541
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01529853
Drug: SAR156597
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT01529853
Drug: Placebo (for SAR156597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT01411176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is included same additives as active comparator.
Study: NCT03761225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02074319
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment as usual or standard treatment for psychosis will be common in all arms
Study: NCT02173249
Drug: AC 170 0.24%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye 2 times daily for 1 week
Study: NCT01882088
Drug: Mucofalk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
Study: NCT00128908
Drug: Rapidly Cycled HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00507832
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: twice daily topical
Study: NCT00938587
Drug: PF-04171327 10 mg
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-04171327 10 mg tablet every day for 14 days
Study: NCT03274752
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.
Study: NCT03003000
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03003000
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03003000
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03326752
Drug: DV281 (RP2D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.
Study: NCT02089087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04129775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratympanic injection of placebo
Study: NCT02592434
Drug: CP-690,550 (tofacitinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.~During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.~Body Weight (Dosage in tablet \[BID\] or solution \[BID\]):~5\<7kg (2mg or 2mL); 7\<10kg(2.5mg or 2. mL); 10 \<15kg (3mg or 3mL); 15\<25kg (3.5mg or 3.5mL); 25\<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).~Oral solution (1 mg/mL) is used for subjects \<40 kg. Oral tablets (5 mg) are used for subjects \>=40 kg.
Study: NCT02630927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be tested.
Study: NCT03085771
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
Study: NCT01358175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01044758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule twice daily (2 weeks)
Study: NCT00469495
Drug: Anti-helminthic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00465699
Drug: Topical B12 0.07%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00871013
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein days 5-8 continuous infusion
Study: NCT03904693
Drug: Placebo FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
Study: NCT04026022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plaster in the ER or PACU
Study: NCT02586961
Drug: 0.9% saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo:~Nebulized 0.9% saline solution
Study: NCT00367445
Drug: Inhaled Human Insulin (Exubera)
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00475436
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00072826
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03022734
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
Study: NCT01397240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Tab, twice a day, 12 weeks
Study: NCT01438931
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02436707
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04260269
Drug: Fluoropyrimidine
Normalized name: Fluoropyrimidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the assessment of a specific evaluation of cardiac safety for patients with solid tumors who have experienced cardiotoxicity grade 1-4 during treatment with a fluoropyrimidine based treatment and are re-challenged with a different fluoropyrimidine.~This multicentre, retrospective database is built to assess the impact on the cardiac and global safety of two different fluoropyrimidine based treatment regimens, of which the first has caused cardiotoxicity grade 1-4.~Cardiac data will be collected by medical record review from initiation of first fluoropyrimidine-based treatment and switch to second fluoropyrimidine-based treatment until death or last follow-up. Basic demographics, cancer and treatment information from the whole course of cancer until death or last follow-up.
Study: NCT01216046
Drug: VX-809 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, taken once daily
Study: NCT01216046
Drug: VX-770 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, taken once every 12 hours
Study: NCT02502721
Drug: DWC20151
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02502721
Drug: DWC20152
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03502694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo tablets orally.
Study: NCT00546494
Drug: Effexor® (Venlafaxine)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00513266
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00513266
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01914965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
Study: NCT04659317
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated placebo tablets x24, to take po q6 hours as need for pain
Study: NCT00281983
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00281983
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03142893
Drug: Cosyntropin Injectable Product
Normalized name: cosyntropin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: cosyntropin injection is given twice per Inpatient Stay
Study: NCT03142893
Drug: Hydrocortisone Injection
Normalized name: hydrocortisone Injection
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone IV push is given twice per Inpatient Visit
Study: NCT03142893
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for ketoconazole are given 4 times per Inpatient Stay
Study: NCT01701505
Drug: 400uL of Kovacaine Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 unilateral intranasal sprays of 200uL each.
Study: NCT01701505
Drug: 200uL of Kovacaine Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 unilateral intranasal sprays of 100uL each.
Study: NCT00862225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
Study: NCT00862225
Drug: IG-RD-001 / Ze 339
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
Study: NCT04246502
Drug: Capecitabine and Pyrotinib
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pyrotinib 400mg orally daily until progressive disease
Study: NCT00970424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, oral tablet administered once daily on background of pioglitazone
Study: NCT00583102
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin dosage: The first dose level will be lovastatin at 0.5 mg/kg/day. After each patient reaches day 14 subsequent patients will be treated at incrementally increasing doses that are 1 mg/kg/day, 2 mg/kg/day, 4 mg/kg/day, 8 mg/kg/day, 12 mg/kg/day, 18 mg/kg/day, and 24 mg/kg/day. If MTD is not reached at this dose of 24 mg/kg/day further dose escalations will occur with a 33% increase in dose at each level rounded to the nearest mg/kg/day.
Study: NCT00002471
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002471
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002471
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002471
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004982
Drug: Combination Iron Chelation Therapy
Approvals — FDA: no, EMA: no, PMDA: no